ArticleAntimicrobial agents and chemotherapy2020
Natural Polymorphisms in Mycobacterium tuberculosis Conferring Resistance to Delamanid in Drug-Naive Patients.
Open access · hybridAbstract read
In one paragraph
Article in Antimicrobial agents and chemotherapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 22 citations in OpenAlex.
- Synergism in drug combination of new tuberculosis antibiotics for drug-resistantMicrobiology spectrum · 2026Article
- Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid AgainstHealth science reports · 2026Review
- Key Proteins and Enzymatic Mechanisms Underlying Drug Resistance in Mycobacterium tuberculosis.Advances in experimental medicine and biology · 2026Review
- Advancing Tuberculosis Treatment with Next-Generation Drugs and Smart Delivery Systems.Pharmaceutics · 2026Review
- GenoMycAnalyzer: a web-based tool for species and drug resistance prediction for Mycobacterium genomes.BMC genomics · 2024Article
- Investigation of genomic mutations and their association with phenotypic resistance to new and repurposed drugs in Mycobacterium tuberculosis complex clinical isolates.The Journal of antimicrobial chemotherapy · 2023Article
- Delamanid or pretomanid? A Solomonic judgement!The Journal of antimicrobial chemotherapy · 2022Article
- Tuberculosis Phenotypic and Genotypic Drug Susceptibility Testing and Immunodiagnostics: A Review.Frontiers in immunology · 2022Review
- Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field.Frontiers in microbiology · 2022Review
- Comparing treatment strategies to reduce antibiotic resistance in an in vitro epidemiological setting.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-ResistantFrontiers in microbiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 6 countries.
Martina L Reichmuth *Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0001-9345-851X
Rico Hömke *Institute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Kathrin ZürcherInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Peter SanderInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.ORCID 0000-0003-1581-0682
Anchalee AvihingsanonThe HIV Netherlands Australia Thailand (HIV-NAT) Research Collaboration, Thai Red Cross AIDS Research Centre and Tuberculosis Research Unit, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.
Jimena CollantesInstituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
Chloé LoiseauSwiss Tropical and Public Health Institute, Basel, Switzerland.
Sonia BorrellSwiss Tropical and Public Health Institute, Basel, Switzerland.
Miriam ReinhardSwiss Tropical and Public Health Institute, Basel, Switzerland.
Robert J WilkinsonWellcome Centre for Infectious Diseases Research in Africa, University of Cape Town, Cape Town, Republic of South Africa.
Marcel YotebiengNational TB Lab, Kinshasa, Democratic Republic of the Congo.
Lukas FennerInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.ORCID 0000-0003-3309-4835
Erik C BöttgerInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland.
Sebastien GagneuxSwiss Tropical and Public Health Institute, Basel, Switzerland.
Matthias EggerInstitute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Peter M KellerInstitute of Medical Microbiology, University of Zurich, Zurich, Switzerland peter.keller@ifik.unibe.ch.ORCID 0000-0002-2890-5384
University of Bern · CHSwiss Tropical and Public Health Institute · CHUniversity of Zurich · CHAlbert Einstein College of Medicine · USChulalongkorn University · THUniversidad Peruana Cayetano Heredia · PEUniversity of Cape Town · ZA
Funding
North American AIDS Cohorts on Collaboration and Design (NAACCORD)U01AI069918 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Keri Nicole Althoff, RICHARD Douglas MOORE · 2006 to 2026
$65.2MEast Africa International Epidemiology Database to evaluate AIDS (IeDEA) Regional ConsortiumU01AI069911 · NIAID · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI AGGREY SEMWENDERO SEMEERE, Kara Kay Wools-Kaloustian · 2006 to 2026
$57.7MObservational Antiretroviral Studies In Southern Africa (OASIS) CollaborationU01AI069924 · NIAID · UNIVERSITAT BERN · PI Cleophas Chimbetete, Mary-Ann Davies · 2006 to 2026
$55.9MThe Asia-Pacific HIV Research CollaborationU01AI069907 · NIAID · FOUNDATION FOR AIDS RESEARCH · PI ANNETTE H SOHN · 2006 to 2026
$44.8MCCASAnet: Caribbean, Central and South America NetworkU01AI069923 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Pedro Enrique Cahn, Jessica L Castilho · 2006 to 2026
$41.6M"Enhancing Cancer Research in Central Africa IeDEA"U01AI096299 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI Denis Nash, Marcel Yotebieng · 2011 to 2026
$35.8MWADA (West Africa Database on Antiretroviral Therapy) CollaborationU01AI069919 · NIAID · UNIVERSITY OF BORDEAUX II · PI Didier Koumavi Ekouevi, Antoine Jaquet · 2006 to 2026
$29.9MEinstein/Rwanda/DRC Consortium for Research in HIV/HPV/MalignanciesU54CA254568 · NCI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI YOTEBIENG, MARCEL · 2020 to 2024
$5.1MNCI NIH HHS U54 CA254568NIAID NIH HHS U01 AI069907NIAID NIH HHS U01 AI069911NIAID NIH HHS U01 AI069918NIAID NIH HHS U01 AI069919NIAID NIH HHS U01 AI069923NIAID NIH HHS U01 AI069924NIAID NIH HHS U01 AI096299Wellcome Trust 104803Wellcome Trust 203135
Abstract
Mutations in the genes of the F
Indexed as
Mycobacterium tuberculosisPharmaceutical PreparationsTuberculosis, Multidrug-ResistantAfricaAntitubercular AgentsAsiaHumansMicrobial Sensitivity TestsMutationNitroimidazolesOxazolesSouth AmericaAntitubercular AgentsNitroimidazolesOPC-67683OxazolesPharmaceutical Preparationsdelamaniddrug resistancemutationsMycobacterium tuberculosisnatural polymorphismresistance
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.